10.15.20
ProHealth, Inc. has been selected to be an authorized distributor of Uthever NMN (Nicotinamide mononucleotide), an ingredient manufactured by Effepharm. NMN, which is made endogenously from B vitamins in the body, is believed to benefit healthy aging as a cofactor of NAD, which provides energy to cells.
“We’re honored that Effepharm recognized ProHealth’s stellar reputation and 32-year history of offering only the highest quality supplements and chose us to be a distributor for what I believe is the world’s best and purest NMN,” Rich Carson, founder of ProHealth, said.
NMN has been touted as a key anti-aging ingredient in the dietary supplements space, however, its sudden rise in popularity has led to a number of companies selling adulterated products containing little to no NMN, ProHealth said. Some of these supplements have been shown to be tainted with contaminants and heavy metals, the company continued.
“In this market flooded with fake and adulterated NMN, Uthever NMN stands out as a product people can trust to be of exceptionally high quality, purity, and potency,” ProHealth said.
During the development of Uthever NMN, Effepharm conducted research and development through GlaxoSmithKline, a research-based pharmaceutical and healthcare company, and recruited a production management team made up of senior managers from Mars Wrigley. The company’s scientific quality standard setting team is under the direction of a former U.S. Pharmacopoeia scientist who ensures that NMN is in strict compliance with USP quality standards, which are applied to pharmaceutical development and manufacturing globally.
ProHealth reported that every batch of Uthever NMN is third-party tested in an independent U.S. lab, and that Effepharm is the only NMN raw material supplier to date to conduct a human clinical trial on the ingredient, using a multicenter, randomized, double-blind, parallel, placebo-controlled design to evaluate the safety and efficacy of the ingredient. It is anticipated that the clinical trial, which involves 66 subjects being administered either the NMN supplement or placebo over a period of 60 days, will be completed by the end of this year.
“We’re honored that Effepharm recognized ProHealth’s stellar reputation and 32-year history of offering only the highest quality supplements and chose us to be a distributor for what I believe is the world’s best and purest NMN,” Rich Carson, founder of ProHealth, said.
NMN has been touted as a key anti-aging ingredient in the dietary supplements space, however, its sudden rise in popularity has led to a number of companies selling adulterated products containing little to no NMN, ProHealth said. Some of these supplements have been shown to be tainted with contaminants and heavy metals, the company continued.
“In this market flooded with fake and adulterated NMN, Uthever NMN stands out as a product people can trust to be of exceptionally high quality, purity, and potency,” ProHealth said.
During the development of Uthever NMN, Effepharm conducted research and development through GlaxoSmithKline, a research-based pharmaceutical and healthcare company, and recruited a production management team made up of senior managers from Mars Wrigley. The company’s scientific quality standard setting team is under the direction of a former U.S. Pharmacopoeia scientist who ensures that NMN is in strict compliance with USP quality standards, which are applied to pharmaceutical development and manufacturing globally.
ProHealth reported that every batch of Uthever NMN is third-party tested in an independent U.S. lab, and that Effepharm is the only NMN raw material supplier to date to conduct a human clinical trial on the ingredient, using a multicenter, randomized, double-blind, parallel, placebo-controlled design to evaluate the safety and efficacy of the ingredient. It is anticipated that the clinical trial, which involves 66 subjects being administered either the NMN supplement or placebo over a period of 60 days, will be completed by the end of this year.
